GLP-1 drugs and weight loss: separating facts from TikTok takes

What's this video probably claiming?

Josh Peck, who has been public about his own weight loss journey, has built a significant following partly by discussing what worked for him. A 9.9 million view TikTok captioned "It's just a fact" in the GLP-1 category almost certainly involves a strong, declarative claim about semaglutide or a similar drug. The most common versions of this type of content assert something like: GLP-1 drugs are the most effective weight loss tool ever developed, that they "change your brain" around food, or that the weight loss results are permanent if you stay on the medication. These claims land somewhere on a spectrum from mostly accurate to dangerously oversimplified. The confident framing, "it's just a fact," signals the creator is presenting contested or nuanced clinical information as settled and obvious. That framing is worth scrutinizing regardless of which specific claim is being made.

What does the science actually show?

The clinical data on GLP-1 receptor agonists is genuinely impressive, which makes it all the more important to read it carefully. The STEP 1 trial (Wilding et al., 2021, NEJM) showed that semaglutide 2.4mg weekly produced mean weight loss of 14.9% over 68 weeks in adults with obesity, compared to 2.4% with placebo. Tirzepatide data from SURMOUNT-1 (Jastreboff et al., 2022, NEJM) pushed that further, with the highest dose group losing a mean 22.5% of body weight. These are real, large-magnitude effects. But the mechanism claims floating around social media are sloppier. Yes, GLP-1 receptors exist in the brain and these drugs appear to reduce appetite signaling, but framing this as "rewiring your brain" overstates what we know. And the durability question is real: the STEP 4 withdrawal trial (Rubino et al., 2021, JAMA) showed participants who stopped semaglutide regained two-thirds of lost weight within a year.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok GLP-1 content and actual clinical practice is around permanence and universality. Creators who have lost significant weight on these drugs often speak as if the results are self-sustaining or as if the drug works identically for everyone. Neither is true. Response rates vary substantially: in STEP 1, roughly 86% of semaglutide patients lost at least 5% of body weight, but about 14% did not respond meaningfully. The drug also doesn't override metabolic adaptation entirely. A second major distortion is the implicit suggestion that GLP-1s work without lifestyle change. The STEP trials all included behavioral counseling. Isolating the drug effect from that support is something most social media content never bothers to do. Finally, side effect profiles get minimized. Nausea affected roughly 44% of semaglutide participants in STEP 1. Serious gastrointestinal events are less common but real, and the FDA has flagged ongoing safety monitoring requirements for these drug classes.

What should you actually know?

GLP-1 receptor agonists represent a genuine shift in what's pharmacologically achievable for obesity treatment. The effect sizes are large enough that dismissing them as hype would be wrong. But "it's just a fact" is exactly the framing that makes these drugs harder to use responsibly. The facts are more conditional than that. These medications require medical supervision, carry real side effects, and appear to require continued use to maintain results for most people. The weight regain data after discontinuation is not a footnote. It has direct implications for how patients should think about starting treatment, cost, and long-term planning. Compounded versions of semaglutide and tirzepatide have also proliferated, and these are not equivalent to FDA-approved branded formulations in terms of regulatory oversight or verified dosing. Anyone considering these drugs should have a real conversation with a licensed clinician, not base their decision on a 60-second video with a confident caption.